切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2020, Vol. 09 ›› Issue (03) : 236 -239. doi: 10.3877/cma.j.issn.2095-3224.2020.03.005

所属专题: 文献

论著

中山医院结直肠癌MDT讨论治疗策略分析
朱德祥1, 韦烨1, 任黎1, 叶青海2, 王晓颖2, 崔越宏3, 刘天舒3, 周波4, 陈漪5, 王明亮6, 饶圣祥6, 王健7, 丁建勇8, 许剑民1,(), 秦新裕1   
  1. 1. 200032 上海,复旦大学附属中山医院普外科
    2. 200032 上海,复旦大学附属中山医院肝外科
    3. 200032 上海,复旦大学附属中山医院肿瘤内科
    4. 200032 上海,复旦大学附属中山医院介入科
    5. 200032 上海,复旦大学附属中山医院肝内科
    6. 200032 上海,复旦大学附属中山医院放射诊断科
    7. 200032 上海,复旦大学附属中山医院放疗科
    8. 200032 上海,复旦大学附属中山医院胸外科
  • 收稿日期:2020-02-21 出版日期:2020-06-25
  • 通信作者: 许剑民
  • 基金资助:
    国家自然科学青年基金项目(No. 81602036); 上海市科学技术委员会项目(No. 17411951300)

Analysis of treatment strategy after colorectal cancer MDT discussion in Zhongshan Hospital

Dexiang Zhu1, Ye Wei1, Li Ren1, Qinghai Ye2, Xiaoying Wang2, Yuehong Cui3, Tianshu Liu3, Bo Zhou4, Yi Chen5, Mingliang Wang6, Shengxiang Rao6, Jian Wang7, Jianyong Ding8, Jianmin Xu1,(), Xinyu Qin1   

  1. 1. Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China
    2. Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai 200032, China
    3. Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
    4. Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
    5. Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
    6. Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
    7. Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
    8. Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China
  • Received:2020-02-21 Published:2020-06-25
  • Corresponding author: Jianmin Xu
  • About author:
    Corresponding author: Xu Jianmin, Email:
引用本文:

朱德祥, 韦烨, 任黎, 叶青海, 王晓颖, 崔越宏, 刘天舒, 周波, 陈漪, 王明亮, 饶圣祥, 王健, 丁建勇, 许剑民, 秦新裕. 中山医院结直肠癌MDT讨论治疗策略分析[J]. 中华结直肠疾病电子杂志, 2020, 09(03): 236-239.

Dexiang Zhu, Ye Wei, Li Ren, Qinghai Ye, Xiaoying Wang, Yuehong Cui, Tianshu Liu, Bo Zhou, Yi Chen, Mingliang Wang, Shengxiang Rao, Jian Wang, Jianyong Ding, Jianmin Xu, Xinyu Qin. Analysis of treatment strategy after colorectal cancer MDT discussion in Zhongshan Hospital[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2020, 09(03): 236-239.

目的

分析结直肠癌多学科诊疗团队(MDT)讨论后制定的治疗策略。

方法

回顾性分析2010年7月至2019年2月复旦大学附属中山医院进行MDT讨论的结直肠癌患者的临床资料,对MDT讨论结果进行统计分析。

结果

结直肠癌MDT总计为1 953例结直肠癌患者进行4 535人次讨论制定个体化治疗方案。其中,553例患者肝转移灶和111例患者肺转移灶被认为可切除。另有261位最初不可切除的结直肠癌肝转移患者,在接受系统化疗联合分子靶向以及介入等综合治疗后,转化为可切除,建议接受肝转移灶切除手术。实际上总计772位结直肠癌患者接受肝转移灶切除,其中同时性肝转移患者有581例,而接受结直肠癌原发灶和肝转移灶同步切除的患者有248例。肝切除手术中仅有87例患者(11.3%)实施解剖性肝切除,绝大多数实施非解剖性肝切除。肝转移灶切除手术中联合射频消融的有62例(8.0%)。术后病理提示R1切除的有18位(2.3%)。

结论

复杂结直肠癌病例推荐行MDT讨论。扩展手术适应证、应用二步肝切除术、联合射频消融等局部毁损治疗可以扩大肝转移灶手术的适应人群。初始无法手术切除的患者,如状况耐受,建议给予强烈的个体化转化治疗,争取转化后手术切除。

Objective

To explore the role of multidisciplinary team (MDT) in the diagnosis and treatment of patients with colorectal cancer.

Methods

A retrospective analysis of CRC patients who underwent MDT discussions from July 2010 to February 2019 at Zhongshan Hospital, Fudan University was conducted and analyzed.

Results

A total of 4 535 MDT discussions developed individualized treatment regimens for 1 953 patients with CRC. Among them, 553 patients with liver metastases and 111 with lung metastases were considered to be resectable. Moreover, 261 patients with initially unresectable colorectal liver metastases were converted to resectable after receiving comprehensive treatment. Actually a total of 772 patients underwent hepatectomy, including 581 patients with synchronous liver metastases, and 248 patients received simultaneous resection of primary colorectal cancer and liver metastases. Only 87 patients (11.3%) underwent anatomical hepatectomy, while the vast majority performed non-anatomical hepatectomy. Sixty-two patients (8.0%) underwent hepatectomy combined with intraoperative radiofrequency ablation. Postoperative pathology results revealed 18 (2.3%) cases of R1 resection.

Conclusion

MDT discussion is recommended for patients with complex CRC. Expanding surgical indications, applying two-step hepatectomy, and combination with radiofrequency ablation can expand the population who underwent metastases surgery. For patients with initially unresectable metastases, it is recommended to perform strong individualized conversion therapy for secondary surgical resection if fit.

[1]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA: a cancer journal for clinicians, 2016, 66(2): 115-132.
[2]
Biasco G, Derenzini E, Gl Grazi, et al. Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties [J]. Cancer Treat Rev, 2006, 32(3): 214-228.
[3]
Emmanuel Mitry, Boris Guiu, Simona Cosconea, et al. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study [J]. Gut, 2010, 59(10): 1383-1388.
[4]
赵志勋,裴炜,熊斌, 等. 结直肠癌腹膜转移诊治中国专家意见(2017) [J/CD]. 中华结直肠疾病电子杂志, 2017, 6(5): 360-366.
[5]
Xu F, Tang B, Jin TQ, et al. Current status of surgical treatment of colorectal liver metastases [J]. World J Clin Cases, 2018, 6(14): 716-734.
[6]
中华医学会外科分会胃肠外科学组,中华医学会外科分会结直肠外科学组,中国抗癌协会大肠癌专业委员会, 等.中国结直肠癌肝转移诊断和综合治疗指南(V 2018) [J/CD].中华结直肠疾病电子杂志, 2018, 7(4): 302-314.
[7]
De Greef K, Rolfo C, Russo A, et al. Multisciplinary management of patients with liver metastasis from colorectal cancer [J]. World J Gastroenterol, 2016, 22(32): 7215-7225.
[8]
Cornelis J H van de Velde, Petra G Boelens, Josep M Borras, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum [J]. Eur J Cancer (Oxford, England : 1990), 2014, 50(1): 1.
[9]
Wale A, Wexner SD, Saur NM, et al. Session 1: The evolution and development of the multidisciplinary team approach: USA, European and UK experiences-what can we do better? [J]. Colorectal Dis, 2018, 20(Suppl 1): 17-27.
[10]
Alastair Munro, Mhari Brown, Paddy Niblock, et al. Do Multidisciplinary Team (MDT) processes influence survival in patients with colorectal cancer? A population-based experience [J]. BMC cancer, 2015, 15: 686.
[11]
Zhu DX, Ren L, Wei Y, et al. Outcome of patients with colorectal liver metastasis: analysis of 1, 613 consecutive cases [J]. Ann Surg Oncol, 2012, 19(9): 2860-2868.
[12]
Breugom AJ, Boelens PG, van den Broek CBM, et al. Quality assurance in the treatment of colorectal cancer: the EURECCA initiative [J]. Ann Oncol, 2014, 25(8): 1485-1492.
[13]
Muralee Menon, Chris Cunningham, David Kerr. Addressing unwarranted variations in colorectal cancer outcomes: a conceptual approach [J]. Nat Rev Clin Oncol, 2016, 13(11): 706-712.
[14]
Xu JM, Fan J, Qin XY, et al. Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018) [J]. J Cancer Res Clin Oncol, 2019, 145(3): 725-736.
[15]
Timothy M Pawlik, Richard D Schulick, Michael A Choti. Expanding criteria for resectability of colorectal liver metastases [J]. The oncologist, 2008, 13(1): 51-64.
[16]
Michael A Choti, Michele Thomas, Schiffon L Wong, et al. Surgical Resection Preferences and Perceptions among Medical Oncologists Treating Liver Metastases from Colorectal Cancer [J]. Ann Surg Oncol, 2016, 23(2): 375-381.
[17]
Wang Z, Peng YF, Hu JW, et al. Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular Carcinoma: A Single Center Study of 45 Patients [J]. Ann Surg, 2020, 271(3): 534-541.
[18]
Alfred Wei Chieh Kow. Hepatic metastasis from colorectal cancer [J]. J Gastrointest Oncol, 2019, 10(6): 1274-1298.
[19]
Hideo Takahashi, Eren Berber. Role of thermal ablation in the management of colorectal liver metastasis [J]. Hepatobiliary Surg Nutr, 2020, 9(1): 49-58.
[20]
Donatella Marino, Francesco Leone, Francesca D′Avanzo, et al. Potentially resectable metastatic colorectal cancer: an individualized approach to conversion therapy [J]. Crit Rev Oncol Hematol, 2014, 92(3): 218-226.
[21]
LiverMetSurvey: International registry of patients operated for colorectal liver metastasis[EB/OL]. [2020-02-20].

URL    
[1] 康夏, 田浩, 钱进, 高源, 缪洪明, 齐晓伟. 骨织素抑制破骨细胞分化改善肿瘤骨转移中骨溶解的机制研究[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 329-339.
[2] 代莉, 邓恢伟, 郭华静, 黄芙蓉. 术中持续输注艾司氯胺酮对腹腔镜结直肠癌手术患者术后睡眠质量的影响[J]. 中华普通外科学文献(电子版), 2023, 17(06): 408-412.
[3] 王得晨, 杨康, 杨自杰, 归明彬, 屈莲平, 张小凤, 高峰. 结直肠癌微卫星稳定状态和程序性死亡、吲哚胺2,3-双加氧酶关系的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 462-465.
[4] 付佳, 肖海敏, 武曦, 冯涛, 师帅. 年龄校正查尔森合并症指数对腹腔镜结直肠癌围手术期并发症的预测价值[J]. 中华普通外科学文献(电子版), 2023, 17(05): 336-341.
[5] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[6] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[7] 李婷, 张琳. 血清脂肪酸代谢物及维生素D水平与结直肠癌发生的关系研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 661-665.
[8] 常剑, 邱峰, 毛郁琪. 摄食抑制因子-1与腹腔镜结直肠癌根治术后肝转移的关系分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 502-505.
[9] 王晓燕, 肖佑, 肖戈, 王真权. 老年结直肠癌肺转移CT特征及高危因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 506-509.
[10] 魏小勇. 原发性肝癌转化治疗焦点问题探讨[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 602-607.
[11] 杜锡林, 谭凯, 贺小军, 白亮亮, 赵瑶瑶. 肝细胞癌转化治疗方式[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 597-601.
[12] 关旭, 王锡山. 基于外科与免疫视角思考结直肠癌区域淋巴结处理的功与过[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 448-452.
[13] 顾睿祈, 方洪生, 蔡国响. 循环肿瘤DNA检测在结直肠癌诊治中的应用与进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 453-459.
[14] 倪文凯, 齐翀, 许小丹, 周燮程, 殷庆章, 蔡元坤. 结直肠癌患者术后发生延迟性肠麻痹的影响因素分析[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 484-489.
[15] 范小彧, 孙司正, 鄂一民, 喻春钊. 梗阻性左半结肠癌不同手术治疗方案的选择应用[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 500-504.
阅读次数
全文


摘要